At a Glance
- Companies: Bristol Myers Squibb; Janux Therapeutics, Inc.
- Location: New York, USA (BMS); San Diego, California (Janux)
- Deal value: $50m upfront/near‑term; up to $800m milestones; tiered royalties
- Focus area: Tumor‑activated T‑cell engager for solid tumors
- Next steps: Janux completes preclinical; BMS leads clinical development
What happened?
Bristol Myers Squibb entered a collaboration and exclusive worldwide license agreement with Janux Therapeutics to co‑develop a novel tumor‑activated T‑cell engager targeting a validated solid tumor antigen across multiple cancer types. Janux receives $50 million upfront and near‑term milestones, up to $800 million in further biobucks, and tiered royalties on global sales.
Why does it matter?
Solid tumors resist conventional T‑cell engagers due to systemic toxicity; Janux’s TRACTr platform uses protease‑cleavable masks to activate selectively in tumor microenvironments, potentially improving safety/efficacy over naked TCEs. BMS gains differentiated next‑gen immuno‑oncology amid patent cliffs for Opdivo/Yervoy.
Who’s behind it?
Janux develops tumor‑activated platforms (TRACTr, TRACIr, ARM) with prior Merck deal; two clinical TCEs in phase 1 prostate cancer. BMS bolsters oncology via external innovation post‑Karuna ($14bn), RayzeBio ($4.1bn).
How was it achieved?
Janux handles preclinical through IND submission; BMS holds IND, leads clinical/commercialization (Janux supports phase 1). Antigen undisclosed but expressed across solid tumors (lung, breast, colon, pancreas).
What’s next?
BMS advances into clinic post‑IND; Janux eligible for milestones through commercialization. Shares rose 12% premarket on validation of masked TCE approach.
What are people saying?
Janux CEO David Campbell: “Combines our innovative technology with BMS’s clinical/commercial expertise.” William Blair: “Further validation reinforcing TRACTr differentiation.”